Strides Arcolab has received United States Food and Drug Administration (USFDA) approval for Acarbose Tablets, 25mg, 50mg and 100mg. Acarbose is a niche anti-diabetic drug used to treat type 2 diabetes mellitus. According to March 2011 IMS data, total US market for Acarbose Tablets approximated to $21 million with no Indian generic players in the market.
The Pharma division has a total of 37 filings with USFDA out of which 21 under the PEPFAR programme and 16 as Generics. Approvals to date are 22, 17 under PEPFAR and 5 Generics. This product will be marketed and sold by Perrigo under a profit share partnership. Product is expected to be launched shortly within Q3’ 2011.
Recently, Onco Therapies, a division of Agila, which is a wholly owned subsidiary of Strides Arcolab, had received United States Food and Drug Administration (US FDA) approval for Gemcitabine for Injection USP in 200mg, 1 gm and 2 gm dosage forms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.90 |
| Dr. Reddys Lab | 1234.40 |
| Cipla | 1232.35 |
| Zydus Lifesciences | 936.50 |
| Lupin | 2328.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: